Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy.
Melanoma News
Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis
Patients who have the low-count chronic lymphocytic leukemia (CLL) phenotype monoclonal B-cell lymphocytosis (LC-MBL) have a nearly doubled risk for melanoma, according to a study in Journal of Clinical Oncology.
Study Highlights Racial Differences in Second Primary Melanoma
White patients have the highest absolute risk for a second primary melanoma, while Black and Asian or Pacific Islander patients have the highest relative risk compared with the general population, a study analyzing Surveillance, Epidemiology, and End Results (SEER) data report.
Gene editing restores treatment sensitivity in melanoma
In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.